UroGen Pharma (URGN) Raw Materials (2020 - 2021)

UroGen Pharma's (URGN) quarterly Raw Materials came in at $2.4 million in Q1 2021, up 132.45% on a QoQ basis from $1.1 million in Q4 2020.

UroGen Pharma (URGN) Raw Materials (2020 - 2021) Analysis & Trends

UroGen Pharma (URGN) has 2 years of Raw Materials data on file, last reported at $2.4 million in Q1 2021.

Quarterly Raw Materials changed N/A year-over-year to $2.4 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $2.4 million (changed N/A YoY) and the FY2020 annual result came in at $1.1 million, changed N/A from the prior year.
Raw Materials grew to $2.4 million in Q1 2021, from $1.1 million in the prior quarter.
In the past five years, Raw Materials ranged from a high of $2.4 million in Q1 2021 to a low of $893000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	UroGen Pharma	2.36 Bn	2.25 Bn	65.88 Mn

Download Data